Apolipoprotein B-containing lipoprotein particle

Apolipoprotein B-containing lipoprotein particles are macromolecular complexes responsible for the transport of triglycerides and cholesterol in the bloodstream, essential for lipid and energy metabolism[1][3][4][5]. They include low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and chylomicron particles, all of which are structurally organized by a single large apolipoprotein B molecule enveloping the particle and mediating its metabolism and tissue uptake[1][2][3][5]. These particles are central to the development of atherosclerotic cardiovascular disease, particularly through their role in cholesterol deposition in vascular walls[1][3][4][6]. Targeting the synthesis or clearance of ApoB-containing lipoprotein particles is a principal therapeutic approach for reducing cardiovascular risk, though clinical interventions must account for potential hepatic and metabolic side effects[4]. Laboratory measurement of circulating ApoB is a widely used biomarker for assessing cardiovascular disease risk and monitoring lipid-lowering therapies[4].

Other names

Apolipoprotein B lipoprotein particleApoB-containing lipoproteinApoB particleNon-HDL lipoprotein particle

Antisense oligonucleotide inhibition of ApoB synthesis (e.g., mipomersen); Inhibition of lipoprotein assembly (e.g., lomitapide, via microsomal triglyceride transfer protein inhibition); Indirect reduction of ApoB-containing particles by decreased LDL synthesis or increased clearance (statins, PCSK9 inhibitors, ezetimibe)